FSI Stanford Events

Clopidogrel Versus Aspirin for Secondary Prophylaxis of Thrombotic Events: A Cost-Effectiveness Analysis

CHP/PCOR Seminar

Date and Time
February 9, 2000
1:30 PM - 3:00 PM

Availability
Open to the Public

Speaker
Mark Schleinitz - VA Fellow at PCOR

Location
2nd floor conference room, CHP/PCOR, 179 Encina Commons

Events of interest

Cost-Effectiveness Analysis of HIV Vaccines
DK Owens
A Cost-effectiveness Analysis of Reimbursement by Capitation vs. Fee-for-service for Severely Ill Medicaid Patients
Richard Grieve, PhD, MSc
Cost-Effectiveness Analyses: Cost-Effectiveness of Vaccinating College Freshmen against Meningitis
Gillian D. Sanders, P Bilir, C Rydzak
A Cost-Effectiveness Analysis of Treatments for Dysplasia in Barrett's Esophagus
Rohini Vij

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis
MD Schleinitz, JP Weiss, Douglas K. Owens, DA Socks
American Journal of Medicine vol. 116, 12 (2004)
Cost-Effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients with Non-Valvular Atrial Fibrillation
BF Gage, AB Cardinalli, GW Albers, Douglas K. Owens
Journal of the American Medical Association vol. 274 (1995)
Cost-Comparison Analysis Versus Cost-Effectiveness Analysis: An Important Difference
S. Chen, A.M. Bayoumi, Mary K. Goldstein
Journal of the American Academy of Dermatology vol. 49 (1999)
Monitored Isoniazid Prophylaxis for Low-Risk Tuberculin Reactors over Age 35: A Risk-Benefit and Cost-Effectiveness Analysis
SR Salpeter, Gillian D. Sanders, EE Salpeter, Douglas K. Owens
Annals of Internal Medicine vol. 127 (1997)